[1] Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol , 2006, 45(4): 529-538. [2] Jia F, Zhang YZ, Liu CM. Stable inhibition of hepatitis B virus expression and replication in HepG2.2.15 cells by RNA interference based on retrovirus delivery. J Biotechnol , 2007, 128(1): 32-40. [3] Weber ND, Stone D, Sedlak RH, De Silva FHS, Roychoudhury P, Schiffer JT, Aubert M, Jerome KR. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One , 2014, 9(5): e97579. [4] Chen JL, Zhang W, Lin JY, Wang F, Wu M, Chen CC, Zheng Y, Peng XH, Li JH, Yuan ZH. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther, 2014, 22(2): 303-311. [5] Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, zur Wiesch JS, Hauber J. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep , 2015, 5: 13734. [6] Liu J, Gaj T, Wallen MC, Barbas CF. Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids , 2015, 4: e232. [7] Wade M. High-Throughput silencing using the CRISPR- Cas9 system: A review of the benefits and challenges. J Biomol Screen , 2015, 20(8): 1027-1039. [8] Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron , 1998, 54(14): 3607-3630. [9] Latorra D, Campbell K, Wolter A, Michael Hurley J. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum Mutat , 2003, 22(1): 79-85. [10] Fluiter K, Ten Asbroek ALMA, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucl Acids Res , 2003, 31(3): 953-962. [11] Brunet E, Alberti P, Perrouault L, Babu R, Wengel J, Giovannangeli C. Exploring cellular activity of locked nucleic acid-modified triplex-forming oligonucleotides and defining its molecular basis. J Biol Chem , 2005, 280(20): 20076-20085. [12] Sun Z, Xiang WQ, Guo YJ, Chen Z, Liu W, Lu DR. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription. Biochem Biophys Res Commun , 2011, 409(3): 430-435. [13] Wah DA, Bitinaite J, Schildkraut I, Aggarwal AK. Structure of Fok I has implications for DNA cleavage. Proc Natl Acad Sci USA , 1998, 95(18): 10564-10569. [14] Li T, Huang S, Jiang WZ, Wright D, Spalding MH, Weeks DP, Yang B. TAL nucleases (TALNs): Hybrid proteins composed of TAL effectors and Fok I DNA-cleavage domain. Nucleic Acids Res , 2011, 39(1): 359-372. [15] Miller JC, Holmes MC, Wang JB, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol , 2007, 25(7): 778-785. [16] Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A. Development of a single-chain, quasi-dimeric zinc- finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucl Acids Res , 2008, 36(12): 3926-3938. [17] Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, Ponomarev V, Cartegni L, Manova K, Rosen N, Benezra R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo . Nat Biotechnol , 2008, 26(1): 91-100. [18] Lu K, Duan QP, Ma L, Zhao DX. Chemical strategies for t |